Last updated: November 14, 2022
Sponsor: Qilu Hospital of Shandong University
Overall Status: Active - Recruiting
Phase
4
Condition
Coronavirus
Treatment
N/AClinical Study ID
NCT05625022
Lianhua Qingke and Omicron
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- confirmed Omicron infection by virus testing;
- ≥18 years of age;
- informed consent provided.
Exclusion
Exclusion Criteria:
- overt bacterial infection in the respiratory tract resulting from common pathologies,including primary immunodeficiency disease, acquired immunodeficiency syndrome,congenital respiratory malformation, congenital heart disease, gastroesophageal refluxdisease, and abnormal lung development;
- asthma treated daily, chronic airway disease, respiratory bacterial infections (e.g.,purulent tonsillitis), acute tracheobronchitis, sinusitis, otitis media, and furtherrespiratory tract pathologies potentially affecting the trial's data analysis;
- common pulmonary diseases (e.g., severe pulmonary interstitial lesions andbronchiectasis) confirmed by chest CT;
- severe pneumonia requiring ventilator use;
- previous or present diseases potentially affecting trial participation or influencingstudy outcome, based on the investigator's judgment;
- pregnancy or lactation in women;
- participation in a clinical study in the past 3 months;
- history of allergy to ≥2 drugs or foods or known allergy to the drug's constituents.
Study Design
Total Participants: 2000
Study Start date:
November 01, 2022
Estimated Completion Date:
December 31, 2023
Connect with a study center
International Convention and Exhibition Center Shelter Hospital
Urumqi, Xinjiang 831400
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.